Genfit (OTCMKTS:GNFTF) Trading Down 2.5%

Genfit SA (OTCMKTS:GNFTF) dropped 2.5% during trading on Wednesday . The stock traded as low as $15.33 and last traded at $15.33, approximately 379 shares traded hands during mid-day trading. A decline of 76% from the average daily volume of 1,548 shares. The stock had previously closed at $15.72.

The firm’s 50-day simple moving average is $14.88 and its two-hundred day simple moving average is $17.84.

About Genfit (OTCMKTS:GNFTF)

Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, and autoimmune or fibrotic diseases affecting primarily the liver and gastro-enterology. The company's lead products include Elafibranor, which is in pivotal Phase 3 clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as in Phase 2 study in patients with primary biliary cholangitis; and Nitazoxanide that is in Phase 2 proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis.

Recommended Story: Are we seeing the beginning of a new bubble?

Receive News & Ratings for Genfit Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genfit and related companies with MarketBeat.com's FREE daily email newsletter.